Damyanti Kerai

Research Analyst at HSBC Securities

Damyanti Kerai is an equity research analyst at HSBC Securities, specializing in coverage of the Indian healthcare and pharmaceutical sectors, with a focus on major listed companies including Dr. Reddy’s Laboratories, Cipla, Lupin, Divi’s Laboratories, Max Healthcare Institute, and Alembic Pharmaceuticals. She covers approximately 20 companies and has a track record marked by a 22% profitable recommendation rate and an average return per transaction of around -5.6%, with her most profitable single trade delivering an 8.2% return. Kerai's analyst career at HSBC began prior to 2024 and she is regularly referenced in coverage by top Indian pharmaceutical firms, although specific prior employment details are not publicly disclosed. She is listed as an official HSBC analyst on multiple company investor relations documents, and is reachable via a corporate HSBC email; however, disclosed documentation of FINRA or equivalent securities licenses is not presently available.